Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026
Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026
Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026
Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC

Fineline Cube Sep 1, 2022

China’s Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug...

Company

RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales

Fineline Cube Sep 1, 2022

China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for...

Policy / Regulatory

Beijing Adjusts UEBMI Account Management, Boosting Outpatient Coverage

Fineline Cube Aug 31, 2022

The Beijing Municipal Medical Insurance Bureau has adjusted the management of Urban Employee Basic Medical...

Company

Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop

Fineline Cube Aug 31, 2022

Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05...

Company Drug

Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases

Fineline Cube Aug 31, 2022

Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...

Company Deals

RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China

Fineline Cube Aug 31, 2022

US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company,...

Company Drug

Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction

Fineline Cube Aug 31, 2022

Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs

Fineline Cube Aug 31, 2022

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised...

Company Deals

Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines

Fineline Cube Aug 31, 2022

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise...

Company

MicroPort Scientific Posts 10% Revenue Growth Despite COVID-19 in 2022 Interim Results

Fineline Cube Aug 31, 2022

China-based MicroPort Scientific Corp. (HKG: 0853) reported unaudited 2022 interim results ending June 30, 2022,...

Company Drug

Merck’s Gardasil 9-Valent HPV Vaccine Approved for Expanded Age Range in China

Fineline Cube Aug 31, 2022

US-based Merck Sharp & Dohme (MSD; NYSE: MRK) announced that China’s National Medical Products Administration...

Company Deals

Onekdrug Raises Series B+ Funding to Boost Pharmaceutical B2B Services

Fineline Cube Aug 31, 2022

Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of...

Company Drug

Sinocelltech’s Ripertamab Wins NMPA Approval for DLBCL Treatment

Fineline Cube Aug 31, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has received New Drug Application (NDA) approval from the...

Company

Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion

Fineline Cube Aug 30, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion)...

Company Drug

Clover Biopharma’s SCB-2019 Vaccine Shows Strong Immune Response to Omicron BA.5

Fineline Cube Aug 30, 2022

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) announced positive Phase II/III trial results for its COVID-19...

Company Drug

Staidson and J&J’s Teclistamab Gain Breakthrough Designation for Hemophilia and Myeloma

Fineline Cube Aug 30, 2022

The Center for Drug Evaluation (CDE) has indicated that Staidson (Beijing) Pharmaceutical Co., Ltd’s (SHE:...

Company Deals

Fosun Pharma to Invest RMB 1B in Chengdu Vaccine Base

Fineline Cube Aug 30, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its subsidiaries, Shanghai Fosun Pharmaceutical...

Company Drug

InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review

Fineline Cube Aug 30, 2022

The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...

Company Deals Digital

Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D

Fineline Cube Aug 30, 2022

Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised...

Company Drug

Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial

Fineline Cube Aug 30, 2022

China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...

Posts pagination

1 … 670 671 672 … 706

Recent updates

  • China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion
  • Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System
  • Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01
  • Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend
  • Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.